Pathogenesis of crohn's disease

F1000Prime Reports

Volumn 7, Issue , 2015, Pages

  Boyapati, Ray ^a,b   Satsangi, Jack ^a,b   Ho, Gwo Tzer ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; INTERLEUKIN 10; INTERLEUKIN 23;

AUTOPHAGY; CROHN DISEASE; ENDOPLASMIC RETICULUM STRESS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; NONHUMAN; PATHOGENESIS; REVIEW; TH17 CELL; UNFOLDED PROTEIN RESPONSE;

EID: 84928038337     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P7-44     Document Type: Review

References (195)

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54. e42; quiz e30.
2. Abraham C, Cho JH: Inflammatory bowel disease. N Engl J Med 2009, 361:2066-78.
3. Peyrin-Biroulet L, Loftus EV, Colombel J, Sandborn WJ: The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010, 105:289-97.
4. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre J, Cosnes J: Predictors of Crohn's disease. Gastroenterology 2006, 130:650-6.
5. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude, C Janneke, Rutgeerts P: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-95.
6. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar J, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, et al.: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-24.
7. Franke A, McGovern, Dermot PB, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, et al.: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010, 42:1118-25.
8. van Limbergen J, Radford-Smith G, Satsangi J: Advances in IBD genetics. Nat Rev Gastroenterol Hepatol 2014, 11:372-85.
9. Hunt KA, Mistry V, Bockett NA, Ahmad T, Ban M, Barker JN, Barrett JC, Blackburn H, Brand O, Burren O, Capon F, Compston A, Gough, Stephen CL, Jostins L, Kong Y, Lee JC, Lek M, MacArthur DG, Mansfield JC, Mathew CG, Mein CA, Mirza M, Nutland S, Onengut-Gumuscu S, Papouli E, Parkes M, Rich SS, Sawcer S, Satsangi J, Simmonds MJ, et al.: Negligible impact of rare autoimmunelocus coding-region variants on missing heritability. Nature 2013, 498:232-5.
10. Ventham NT, Kennedy NA, Nimmo ER, Satsangi J: Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology 2013, 145:293-308.
11. Adams AT, Kennedy NA, Hansen R, Ventham NT, O'Leary KR, Drummond HE, Noble CL, El-Omar E, Russell RK, Wilson DC, Nimmo ER, Hold GL, Satsangi J: Two-stage genome-wide methylation profiling in childhood-onset Crohn's Disease implicates epigenetic alterations at the VMP1/MIR21 and HLA loci. Inflamm Bowel Dis 2014, 20:1784-93.
12. Nimmo ER, Stevens C, Phillips AM, Smith A, Drummond HE, Noble CL, Quail M, Davies G, Aldhous MC, Wilson DC, Satsangi J: TLE1 modifies the effects of NOD2 in the pathogenesis of Crohn's disease. Gastroenterology 2011, 141:972-981.e1-2.
13. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
14. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-6.
15. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher, Peter JP, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG: The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002, 122:867-74.
16. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nuñez G: Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003, 278:5509-12.
17. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Häfner R, Chamaillard M, Zouali H, Thomas G, Hugot JP: CARD15 mutations in Blau syndrome. Nat Genet 2001, 29:19-20.
18. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, Flavell RA: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005, 307:731-4.
19. Ogura Y, Lala S, Xin W, Smith E, Dowds TA, Chen FF, Zimmermann E, Tretiakova M, Cho JH, Hart J, Greenson JK, Keshav S, Nuñez G: Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003, 52:1591-7.
20. Jiang W, Wang X, Zeng B, Liu L, Tardivel A, Wei H, Han J, MacDonald HR, Tschopp J, Tian Z, Zhou R: Recognition of gut microbiota by NOD2 is essential for the homeostasis of intestinal intraepithelial lymphocytes. J Exp Med 2013, 210:2465-76.
21. Bevins CL, Stange EF, Wehkamp J: Decreased Paneth cell defensin expression in ileal Crohn' s disease is independent of inflammation, but linked to the NOD2 1007fs genotype. Gut 2009, 58:882-3; discussion 883-4.
22. Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, Ferguson, David JP, Campbell BJ, Jewell D, Simmons A: NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010, 16:90-7.
23. Lapaquette P, Bringer M, Darfeuille-Michaud A: Defects in autophagy favour adherent-invasive Escherichia coli persistence within macrophages leading to increased pro-inflammatory response. Cell Microbiol 2012, 14:791-807.
24. van Heel, DA, Ghosh S, Hunt KA, Mathew CG, Forbes A, Jewell DP, Playford RJ: Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut 2005, 54:1553-7.
25. Brain O, Owens, Benjamin MJ, Pichulik T, Allan P, Khatamzas E, Leslie A, Steevels T, Sharma S, Mayer A, Catuneanu AM, Morton V, Sun M, Jewell D, Coccia M, Harrison O, Maloy K, Schönefeldt S, Bornschein S, Liston A, Simmons A: The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release. Immunity 2013, 39:521-36.
26. Nigro G, Rossi R, Commere P, Jay P, Sansonetti PJ: The cytosolic bacterial peptidoglycan sensor Nod2 affords stem cell protection and links microbes to gut epithelial regeneration. Cell Host Microbe 2014, 15:792-8.
27. Strober W, Asano N, Fuss I, Kitani A, Watanabe T: Cellular and molecularmechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease. Immunol Rev 2014, 260:249-60.
28. Uehara A, Yang S, Fujimoto Y, Fukase K, Kusumoto S, Shibata K, Sugawara S, Takada H: Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 2005, 7:53-61.
29. van Heel, David A, Ghosh S, Butler M, Hunt KA, Lundberg, Anna MC, Ahmad T, McGovern Dermot PB, Onnie C, Negoro K, Goldthorpe S, Foxwell, Brian MJ, Mathew CG, Forbes A, Jewell DP, Playford RJ: Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 2005, 365:1794-6.
30. van Beelen, Astrid J, Zelinkova Z, Taanman-Kueter EW, Muller FJ, Hommes DW, Zaat, Sebastian AJ, Kapsenberg ML, de Jong, Esther C: Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 2007, 27:660-9.
31. Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober W: Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 2006, 25:473-85.
32. Yang Z, Fuss IJ, Watanabe T, Asano N, Davey MP, Rosenbaum JT, Strober W, Kitani A: NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction. Gastroenterology 2007, 133:1510-21.
33. Hedl M, Li J, Cho JH, Abraham C: Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci USA 2007, 104:19440-5.
34. Hedl M, Abraham C: Secretory mediators regulate Nod2-induced tolerance in human macrophages. Gastroenterology 2011, 140:231-41.
35. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H, Fellermann K, Ganz T, Stange EF, Bevins CL: Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005, 102:18129-34.
36. VanDussen KL, Liu T, Li D, Towfic F, Modiano N, Winter R, Haritunians T, Taylor KD, Dhall D, Targan SR, Xavier RJ, McGovern, Dermot PB, Stappenbeck TS: Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn's disease. Gastroenterology 2014, 146:200-9.
37. Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL: Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut 2008, 57:903-10.
38. Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, Ogunbiyi O, Nuñez G, Keshav S: Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003, 125:47-57.
39. Knights D, Silverberg MS, Weersma RK, Gevers D, Dijkstra G, Huang H, Tyler AD, van Sommeren S, Imhann F, Stempak JM, Huang H, Vangay P, Al-Ghalith GA, Russell C, Sauk J, Knight J, Daly MJ, Huttenhower C, Xavier RJ: Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Med 2014, 6:107.
40. Petnicki-Ocwieja T, Hrncir T, Liu Y, Biswas A, Hudcovic T, Tlaskalova-Hogenova H, Kobayashi KS: Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA 2009, 106:15813-8.
41. Rehman A, Sina C, Gavrilova O, Häsler R, Ott S, Baines JF, Schreiber S, Rosenstiel P: Nod2 is essential for temporal development of intestinal microbial communities. Gut 2011, 60:1354-62.
42. Ramanan D, Tang MS, Bowcutt R, Loke P, Cadwell K: Bacterial sensor Nod2 prevents inflammation of the small intestine by restricting the expansion of the commensal Bacteroides vulgatus. Immunity 2014, 41:311-24.
43. Robertson SJ, Zhou JY, Geddes K, Rubino SJ, Cho JH, Girardin SE, Philpott DJ: Nod1 and Nod2 signaling does not alter the composition of intestinal bacterial communities at homeostasis. Gut Microbes 2013, 4:222-31.
44. Shanahan MT, Carroll IM, Grossniklaus E, White A, von Furstenberg, Richard J, Barner R, Fodor AA, Henning SJ, Sartor RB, Gulati AS: Mouse Paneth cell antimicrobial function is independent of Nod2. Gut 2014, 63:903-10.
45. Travassos LH, Carneiro Leticia AM, Ramjeet M, Hussey S, Kim Y, Magalhães JG, Yuan L, Soares F, Chea E, Le Bourhis L, Boneca IG, Allaoui A, Jones NL, Nuñez G, Girardin SE, Philpott DJ: Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010, 11:55-62.
46. Caruso R, Warner N, Inohara N, Núñez G: NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity 2014, 41:898-908.
47. Boyle JP, Parkhouse R, Monie TP: Insights into the molecular basis of the NOD2 signalling pathway. Biol Open 2014, 4.
48. Salem M, Seidelin JB, Rogler G, Nielsen OH: Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond. Cell Mol Life Sci 2013, 70:3391-404.
49. Moreira LO, Zamboni DS: NOD1 and NOD2 Signaling in Infection and Inflammation. Front Immunol 2012, 3:328.
50. Philpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE: NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol 2014, 14:9-23.
51. Levine B, Kroemer G: Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
52. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La Vega, Francisco M, Briggs J, Günther S, Prescott NJ, Onnie CM, Häsler R, Sipos B, Fölsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S: A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007, 39:207-11.
53. Murthy A, Li Y, Peng I, Reichelt M, Katakam AK, Noubade R, Roose-Girma M, DeVoss J, Diehl L, Graham RR, van Lookeren Campagne Menno: A Crohn' s disease variant in Atg16l1 enhances its degradation by caspase 3. Nature 2014, 506:456-62.
54. Lassen KG, Kuballa P, Conway KL, Patel KK, Becker CE, Peloquin JM, Villablanca EJ, Norman JM, Liu T, Heath RJ, Becker ML, Fagbami L, Horn H, Mercer J, Yilmaz OH, Jaffe JD, Shamji AF, Bhan AK, Carr SA, Daly MJ, Virgin HW, Schreiber SL, Stappenbeck TS, Xavier RJ: Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Proc Natl Acad Sci U S A 2014, 111:7741-6.
55. Sorbara MT, Ellison LK, Ramjeet M, Travassos LH, Jones NL, Girardin SE, Philpott DJ: The protein ATG16L1 suppresses inflammatory cytokines induced by the intracellular sensors Nod1 and Nod2 in an autophagy-independent manner. Immunity 2013, 39:858-73.
56. McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J,Wysoker A, Shapero MH, de Bakker, Paul IW, Maller JB, Kirby A, Elliott AL, Parkin M, Hubbell E,Webster T, Mei R, Veitch J, Collins PJ, Handsaker R, Lincoln S, Nizzari M, Blume J, Jones KW, Rava R, Daly MJ, Gabriel SB, Altshuler D: Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet 2008, 40:1166-74.
57. MacMicking JD, Taylor GA, McKinney JD: Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003, 302:654-9.
58. Henry SC, Daniell X, Indaram M, Whitesides JF, Sempowski GD, Howell D, Oliver T, Taylor GA: Impaired macrophage function underscores susceptibility to Salmonella in mice lacking Irgm1 (LRG-47). J Immunol 2007, 179:6963-72.
59. Collazo CM, Yap GS, Sempowski GD, Lusby KC, Tessarollo L, Vande Woude GF, Sher A, Taylor GA: Inactivation of LRG-47 and IRG-47 reveals a family of interferon gamma-inducible genes with essential, pathogen-specific roles in resistance to infection. J Exp Med 2001, 194:181-8.
60. Singh SB, Davis AS, Taylor GA, Deretic V: Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006, 313:1438-41.
61. Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, Mari B, Barbry P, Mosnier J, Hébuterne X, Harel-Bellan A, Mograbi B, Darfeuille-Michaud A, Hofman P: A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet 2011, 43:242-5.
62. Liu B, Gulati AS, Cantillana V, Henry SC, Schmidt EA, Daniell X, Grossniklaus E, Schoenborn AA, Sartor RB, Taylor GA: Irgm1-deficient mice exhibit Paneth cell abnormalities and increased susceptibility to acute intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2013, 305:G573-84.
63. Roberts RL, Hollis-Moffatt JE, Gearry RB, Kennedy MA, Barclay ML, Merriman TR: Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort. Genes Immun 2008, 9:561-5.
64. Feng CG, Zheng L, Jankovic D, Báfica A, Cannons JL, Watford WT, Chaussabel D, Hieny S, Caspar P, Schwartzberg PL, Lenardo MJ, Sher A: The immunity-related GTPase Irgm1 promotes the expansion of activated CD4+ T cell populations by preventing interferon-gamma-induced cell death. Nat Immunol 2008, 9:1279-87.
65. Feng CG, Weksberg DC, Taylor GA, Sher A, Goodell MA: The p47 GTPase Lrg-47 (Irgm1) links host defense and hematopoietic stem cell proliferation. Cell Stem cell 2008, 2:83-9.
66. Bekpen C, Hunn JP, Rohde C, Parvanova I, Guethlein L, Dunn DM, Glowalla E, Leptin M, Howard JC: The interferon-inducible p47 (IRG) GTPases in vertebrates: loss of the cell autonomous resistance mechanism in the human lineage. Genome Biol 2005, 6:R92.
67. Colgan SP, Taylor CT: Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol 2010, 7:281-7.
68. Glover LE, Colgan SP: Hypoxia and metabolic factors that influence inflammatory bowel disease pathogenesis. Gastroenterology 2011, 140:1748-55.
69. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH: Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004, 114:1098-106.
70. Giatromanolaki A, Sivridis E, Maltezos E, Papazoglou D, Simopoulos C, Gatter KC, Harris AL, Koukourakis MI: Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol 2003, 56:209-13.
71. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouysségur J, Mazure NM: Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 2009, 29:2570-81.
72. Mimouna S, Bazin M, Mograbi B, Darfeuille-Michaud A, Brest P, Hofman P, Vouret-Craviari V: HIF1A regulates xenophagic degradation of adherent and invasive Escherichia coli (AIEC). Autophagy 2014, 10:2333-45.
73. Denizot J, Desrichard A, Agus A, Uhrhammer N, Dreux N, Vouret-Craviari V, Hofman P, Darfeuille-Michaud A, Barnich N: Dietinduced hypoxia responsive element demethylation increases CEACAM6 expression, favouring Crohn's disease-associated Escherichia coli colonisation. Gut 2015, 64:428-37.
74. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP: Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002, 110:993-1002.
75. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002, 62:3387-94.
76. Furuta GT, Turner JR, Taylor CT, Hershberg RM, Comerford K, Narravula S, Podolsky DK, Colgan SP: Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med 2001, 193:1027-34.
77. Louis NA, Hamilton KE, Canny G, Shekels LL, Ho SB, Colgan SP: Selective induction of mucin-3 by hypoxia in intestinal epithelia. J Cell Biochem 2006, 99:1616-27.
78. Nizet V, Johnson RS: Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009, 9:609-17.
79. Gupta R, Chaudhary AR, Shah BN, Jadhav AV, Zambad SP, Gupta RC, Deshpande S, Chauthaiwale V, Dutt C: Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis. Clin Exp Gastroenterol 2014, 7:13-23.
80. Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, Colgan SP: Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 2008, 134:145-55.
81. Cummins EP, Seeballuck F, Keely SJ, Mangan NE, Callanan JJ, Fallon PG, Taylor CT: The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 2008, 134:156-65.
82. Dulai PS, Gleeson MW, Taylor D, Holubar SD, Buckey JC, Siegel CA: Systematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease. Aliment Pharmacol Ther 2014, 39:1266-75.
83. Onyiah JC, Sheikh SZ, Maharshak N, Steinbach EC, Russo SM, Kobayashi T, Mackey LC, Hansen JJ, Moeser AJ, Rawls JF, Borst LB, Otterbein LE, Plevy SE: Carbon monoxide and heme oxygenase-1 prevent intestinal inflammation in mice by promoting bacterial clearance. Gastroenterology 2013, 144:789-98.
84. Onyiah JC, Sheikh SZ, Maharshak N, Otterbein LE, Plevy SE: Heme oxygenase-1 and carbon monoxide regulate intestinal homeostasis and mucosal immune responses to the enteric microbiota. Gut Microbes 2014, 5:220-4.
85. Green DR, Levine B: To be or not to be? How selective autophagy and cell death govern cell fate. Cell 2014, 157:65-75.
86. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin HW: A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008, 456:259-63.
87. Cadwell K, Patel KK, Maloney NS, Liu T, Ng, Aylwin CY, Storer CE, Head RD, Xavier R, Stappenbeck TS, Virgin HW: Virus-plussusceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2010, 141:1135-45.
88. McGovern Dermot PB, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong, Rick TH, Lagacé C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D'Amato M, Halfvarson J, Hibberd ML, Lördal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard E, Deslandres C, Hommes DW, de Jong, Dirk J, Stokkers PC, Weersma RK et al.: Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nature Genet 2010, 42:332-7.
89. Kaser A, Lee A, Franke A, Glickman JN, Zeissig S, Tilg H, Nieuwenhuis Edward ES, Higgins DE, Schreiber S, Glimcher LH, Blumberg RS: XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008, 134:743-56.
90. Zheng W, Rosenstiel P, Huse K, Sina C, Valentonyte R, Mah N, Zeitlmann L, Grosse J, Ruf N, Nürnberg P, Costello CM, Onnie C, Mathew C, Platzer M, Schreiber S, Hampe J: Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes Immun 2006, 7:11-8.
91. Walter P, Ron D: The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011, 334:1081-6.
92. Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, Taupin D, Thornton DJ, Png CW, Crockford TL, Cornall RJ, Adams R, Kato M, Nelms KA, Hong NA, Florin, Timothy HJ, Goodnow CC, McGuckin MA: Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med 2008, 5:e54.
93. Kaser A, Blumberg RS: Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology 2011, 140:1738-47.
94. Ogata M, Hino S, Saito A, Morikawa K, Kondo S, Kanemoto S, Murakami T, Taniguchi M, Tanii I, Yoshinaga K, Shiosaka S, Hammarback JA, Urano F, Imaizumi K: Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 2006, 26:9220-31.
95. Ding W, Ni H, Gao W, Yoshimori T, Stolz DB, Ron D, Yin X: Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 2007, 171:513-24.
96. Yang L, Li P, Fu S, Calay ES, Hotamisligil GS: Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell metabolism 2010, 11:467-78.
97. Fritz T, Niederreiter L, Adolph T, Blumberg RS, Kaser A: Crohn's disease: NOD2, autophagy and ER stress converge. Gut 2011, 60:1580-8.
98. Deegan S, Saveljeva S, Gorman AM, Samali A: Stress-induced selfcannibalism: on the regulation of autophagy by endoplasmic reticulum stress. Cell Mol Life Sci 2013, 70:2425-41.
99. Adolph TE, Tomczak MF, Niederreiter L, Ko H, Böck J, Martinez-Naves E, Glickman JN, Tschurtschenthaler M, Hartwig J, Hosomi S, Flak MB, Cusick JL, Kohno K, Iwawaki T, Billmann-Born S, Raine T, Bharti R, Lucius R, Kweon M, Marciniak SJ, Choi A, Hagen SJ, Schreiber S, Rosenstiel P, Kaser A, Blumberg RS: Paneth cells as a site of origin for intestinal inflammation. Nature 2013, 503:272-6.
100. Maloy KJ, Powrie F: Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306.
101. Peterson LW, Artis D: Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 2014, 14:141-53.
102. Izcue A, Hue S, Buonocore S, Arancibia-Cárcamo CV, Ahern PP, Iwakura Y, Maloy KJ, Powrie F: Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 2008, 28:559-70.
103. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (New York, NY) 2006, 314:1461-3.
104. Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, Robinson N, Buonocore S, Tlaskalova-Hogenova H, Cua DJ, Powrie F: Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006, 25:309-18.
105. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D: IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-6.
106. Ahern PP, Schiering C, Buonocore S, McGeachy MJ, Cua DJ, Maloy KJ, Powrie F: Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010, 33:279-88.
107. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O' Shea JJ, Cua DJ: The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009, 10:314-24.
108. Ghoreschi K, Laurence A, Yang X, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N, Grainger JR, Chen Q, Kanno Y, Watford WT, Sun H, Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O'Shea JJ: Generation of pathogenic T(H)17 cells in the absence of TGF- b signalling. Nature 2010, 467:967-71.
109. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J,O'Farrell A, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal Malefyt, Rene, Moore KW: Areceptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002, 168:5699-708.
110. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-8.
111. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K: Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011, 331:337-41.
112. Ivanov II, Frutos, Rosa de Llanos, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB, Littman DR: Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008, 4:337-49.
113. Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, Yagita H, Ishii N, Evans R, Honda K, Takeda K: ATP drives lamina propria T(H)17 cell differentiation. Nature 2008, 455:808-12.
114. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron J, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt, Rene: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nature Immunol 2007, 8:950-7.
115. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y: Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52:65-70.
116. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y: Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005, 129:969-84.
117. Di Sabatino A, Rovedatti L, Kaur R, Spencer JP, Brown JT, Morisset VD, Biancheri P, Leakey, Nicholas AB, Wilde JI, Scott L, Corazza GR, Lee K, Sengupta N, Knowles CH, Gunthorpe MJ, McLean PG, MacDonald TT, Kruidenier L: Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. J Immunol 2009, 183:3454-62.
118. Kleinschek MA, Boniface K, Sadekova S, Grein J, Murphy EE, Turner SP, Raskin L, Desai B, Faubion WA, de Waal Malefyt, Rene, Pierce RH, McClanahan T, Kastelein RA: Circulating and gutresident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 2009, 206:525-34.
119. Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, Powrie F: Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010, 464:1371-5.
120. Geremia A, Arancibia-Cárcamo CV, Fleming, Myles PP, Rust N, Singh B, Mortensen NJ, Travis, Simon PL, Powrie F: IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011, 208:1127-33.
121. Hepworth MR, Monticelli LA, Fung TC, Ziegler, Carly GK, Grunberg S, Sinha R, Mantegazza AR, Ma H, Crawford A, Angelosanto JM, Wherry EJ, Koni PA, Bushman FD, Elson CO, Eberl G, Artis D, Sonnenberg GF: Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature 2013, 498:113-7.
122. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, GoldfarbKC, SanteeCA, Lynch SV,TanoueT, Imaoka A, ItohK,TakedaK, Umesaki Y, Honda K, Littman DR: Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-98.
123. Davidson NJ, Leach MW, Fort MM, Thompson-Snipes L, Kühn R, Müller W, Berg DJ, Rennick DM: T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996, 184:241-51.
124. Glocker E, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora K, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C: Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009, 361:2033-45.
125. Frank DN, St Amand, Allison L, Feldman RA, Boedeker EC, Harpaz N, Pace NR: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel disease. Proc Natl Acad Sci U S A 2007, 104:13780-5.
126. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J, Blugeon S, Bridonneau C, Furet J, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008, 105:16731-6.
127. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-78.
128. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS: The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013, 341:569-73.
129. Mazmanian SK, Round JL, Kasper DL: A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453:620-5.
130. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H: Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504:446-50.
131. Belkaid Y, Hand TW: Role of the microbiota in immunity and inflammation. Cell 2014, 157:121-41.
132. Huttenhower C, Kostic AD, Xavier RJ: Inflammatory bowel disease as a model for translating the microbiome. Immunity 2014, 40:843-54.
133. Kostic AD, Xavier RJ, Gevers D: The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014, 146:1489-99.
134. Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-94.
135. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998, 114:262-7.
136. Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R, Vantrappen G: Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991, 338:771-4.
137. McGovern Dermot PB, Jones MR, Taylor KD, Marciante K, Yan X, Dubinsky M, Ippoliti A, Vasiliauskas E, Berel D, Derkowski C, Dutridge D, Fleshner P, Shih DQ, Melmed G, Mengesha E, King L, Pressman S, Haritunians T, Guo X, Targan SR, Rotter JI: Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet 2010, 19:3468-76.
138. Pickard JM, Maurice CF, Kinnebrew MA, Abt MC, Schenten D, Golovkina TV, Bogatyrev SR, Ismagilov RF, Pamer EG, Turnbaugh PJ, Chervonsky AV: Rapid fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness. Nature 2014, 514:638-41.
139. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122:44-54.
140. Mondot S, Kang S, Furet JP, Aguirre de Carcer, D, McSweeney C, Morrison M, Marteau P, Doré J, Leclerc M: Highlighting new phylogenetic specificities of Crohn's disease microbiota. Inflamm Bowel Dis 2011, 17:185-92.
141. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J: Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006, 55:205-11.
142. Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Järnerot G, Tysk C, Jansson JK, Engstrand L: A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010, 139:1844-1854.e1.
143. Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, Beaumont M, van Treuren W, Knight R, Bell JT, Spector TD, Clark AG, Ley RE: Human genetics shape the gut microbiome. Cell 2014, 159:789-99.
144. Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H, Zhu W, Sartor RB, Boedeker EC, Harpaz N, Pace NR, Li E: Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011, 17:179-84.
145. Hansen R, Russell RK, Reiff C, Louis P, McIntosh F, Berry SH, Mukhopadhya I, Bisset WM, Barclay AR, Bishop J, Flynn DM, McGrogan P, Loganathan S, Mahdi G, Flint HJ, El-Omar EM, Hold GL: Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Am J Gastroenterol 2012, 107:1913-22.
146. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser A, Barnich N, Bringer M, Swidsinski A, Beaugerie L, Colombel J: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004, 127:412-21.
147. Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM: Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004, 127:80-93.
148. Martinez-Medina M, Aldeguer X, Lopez-Siles M, González-Huix F, López-Oliu C, Dahbi G, Blanco JE, Blanco J, Garcia-Gil LJ, Darfeuille-Michaud A: Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm Bowel Dis 2009, 15:872-82.
149. Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW: Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J 2007, 1:403-18.
150. Barnich N, Carvalho FA, Glasser A, Darcha C, Jantscheff P, Allez M, Peeters H, Bommelaer G, Desreumaux P, Colombel J, Darfeuille-Michaud A: CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 2007, 117:1566-74.
151. Glasser AL, Boudeau J, Barnich N, Perruchot MH, Colombel JF, Darfeuille-Michaud A: Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001, 69:5529-37.
152. Bringer M, Glasser A, Tung C, Méresse S, Darfeuille-Michaud A: The Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 replicates in mature phagolysosomes within J774 macrophages. Cell Microbiol 2006, 8:471-84.
153. Carvalho FA, Barnich N, Sivignon A, Darcha C, Chan, Carlos HF, Stanners CP, Darfeuille-Michaud A: Crohn's disease adherentinvasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med 2009, 206:2179-89.
154. Ott SJ, Kühbacher T, Musfeldt M, Rosenstiel P, Hellmig S, Rehman A, Drews O, Weichert W, Timmis KN, Schreiber S: Fungi and inflammatory bowel diseases: Alterations of composition and diversity. Scand J Gastroenterol 2008, 43:831-41.
155. Mukhopadhya I, Hansen R, Meharg C, Thomson JM, Russell RK, Berry SH, El-Omar EM, Hold GL: The fungal microbiota of denovo paediatric inflammatory bowel disease. Microbes Infect 2014, .
156. Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Kambal A, Monaco CL, Zhao G, Fleshner P, Stappenbeck TS, McGovern Dermot PB, Keshavarzian A, Mutlu EA, Sauk J, Gevers D, Xavier RJ, Wang D, Parkes M, Virgin HW: Diseasespecific alterations in the enteric virome in inflammatory bowel disease. Cell 2015, 160:447-60.
157. Willing B, Halfvarson J, Dicksved J, Rosenquist M, Järnerot G, Engstrand L, Tysk C, Jansson JK: Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis 2009, 15:653-60.
158. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, et al.: The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014, 15:382-92.
159. Papa E, Docktor M, Smillie C, Weber S, Preheim SP, Gevers D, Giannoukos G, Ciulla D, Tabbaa D, Ingram J, Schauer DB, Ward DV, Korzenik JR, Xavier RJ, Bousvaros A, Alm EJ: Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PloS one 2012, 7:e39242.
160. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C: Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012, 13:R79.
161. Haberman Y, Tickle TL, Dexheimer PJ, Kim M, Tang D, Karns R, Baldassano RN, Noe JD, Rosh J, Markowitz J, Heyman MB, Griffiths AM, Crandall WV, Mack DR, Baker SS, Huttenhower C, Keljo DJ, Hyams JS, Kugathasan S, Walters TD, Aronow B, Xavier RJ, Gevers D, Denson LA: Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest 2014, 124:3617-33.
162. Palm NW, de Zoete, Marcel R, Cullen TW, Barry NA, Stefanowski J, Hao L, Degnan PH, Hu J, Peter I, Zhang W, Ruggiero E, Cho JH, Goodman AL, Flavell RA: Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014, 158:1000-10.
163. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, Peaper DR, Bertin J, Eisenbarth SC, Gordon JI, Flavell RA: NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145:745-57.
164. Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, Glickman JN, Glimcher LH: Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007, 131:33-45.
165. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ: Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505:559-63.
166. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD: Linking long-term dietary patterns with gut microbial enterotypes. Science (New York, NY) 2011, 334:105-8.
167. Zimmer J, Lange B, Frick J, Sauer H, Zimmermann K, Schwiertz A, Rusch K, Klosterhalfen S, Enck P: A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 2012, 66:53-60.
168. Rogler G, Vavricka S: Exposome in IBD: Recent Insights in Environmental Factors that Influence the Onset and Course of IBD. Inflamm Bowel Dis 2015, 21:400-8.
169. Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr EJ, Bredin F, Rickman HM, Ratlamwala H, Hatton A, Rayner TF, Parkes M, Smith, Kenneth GC: Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011, 121:4170-9.
170. Lee JC, Espéli M, Anderson CA, Linterman MA, Pocock JM, Williams NJ, Roberts R, Viatte S, Fu B, Peshu N, Hien TT, Phu NH, Wesley E, Edwards C, Ahmad T, Mansfield JC, Gearry R, Dunstan S, Williams TN, Barton A, Vinuesa CG, Parkes M, Lyons PA, Smith Kenneth GC: Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 2013, 155:57-69.
171. Yang S, Hong M, Baek J, Choi H, Zhao W, Jung Y, Haritunians T, Ye BD, Kim K, Park SH, Park S, Yang D, Dubinsky M, Lee I, McGovern Dermot PB, Liu J, Song K: A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014, 46:1017-20.
172. Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, Annese V, Bampton P, Barnardo M, Bell S, Cole A, Connor SJ, Creed T, Cummings FR, D'Amato M, Daneshmend TK, Fedorak RN, Florin TH, Gaya DR, Greig E, Halfvarson J, Hart A, Irving PM, Jones G, Karban A, Lawrance IC et al.: HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014, 46:1131-4.
173. Dorward DA, Lucas CD, Rossi AG, Haslett C, Dhaliwal K: Imaging inflammation: molecular strategies to visualize key components of the inflammatory cascade, from initiation to resolution. Pharmacol Ther 2012, 135:182-99.
174. Panés J, Ricart E, Rimola J: New MRI modalities for assessment of inflammatory bowel disease. Gut 2010, 59:1308-9.
175. Tontini GE, Vecchi M, Neurath MF, Neumann H: Advanced endoscopic imaging techniques in Crohn's disease. J Crohns Colitis 2014, 8:261-9.
176. Kiesslich R, Duckworth CA, Moussata D, Gloeckner A, Lim LG, Goetz M, Pritchard DM, Galle PR, Neurath MF, Watson, AJM: Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 2012, 61:1146-53.
177. Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y, Willma M, App C, Münster T, Kessler H, Maas S, Gebhardt B, Heimke-Brinck R, Reuter E, Dörje F, Rau TT, Uter W, Wang TD, Kiesslich R, Vieth M, Hannappel E, Neurath MF: In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med 2014, 20:313-8.
178. Roberts CL, Keita AV, Duncan SH, O'Kennedy N, Söderholm JD, Rhodes JM, Campbell BJ: Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010, 59:1331-9.
179. Sha S, Liang J, Chen M, Xu B, Liang C, Wei N, Wu K: Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther 2014, 39:1003-32.
180. Sartor RB: Key questions to guide a better understanding of host-commensal microbiota interactions in intestinal inflammation. Mucosal Immunol 2011, 4:127-32.
181. Stevens C, Henderson P, Nimmo ER, Soares DC, Dogan B, Simpson KW, Barrett JC, Wilson DC, Satsangi J: The intermediate filament protein, vimentin, is a regulator of NOD2 activity. Gut 2013, 62:695-707.
182. Rubino SJ, Magalhaes JG, Philpott D, Bahr GM, Blanot D, Girardin SE: Identification of a synthetic muramyl peptide derivative with enhanced Nod2 stimulatory capacity. Innate Immun 2013, 19:493-503.
183. Jakopin ?, Gobec M, Mlinariè-Ra?èan I, Sollner Dolenc M: Immunomodulatory properties of novel nucleotide oligomerization domain 2 (nod2) agonistic desmuramyldipeptides. J Med Chem 2012, 55:6478-88.
184. Massey, DCO, Bredin F, Parkes M: Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 2008, 57:1294-6.
185. Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H: A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-tosevere active Crohn ' s disease. Am J Gastroenterol 2008, 103:2284-92.
186. SandbornWJ, Gasink C, Gao L, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers, Willem JS, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG: Ustekinumab induction andmaintenance therapy in refractory Crohn's disease. N Engl J Med 2012, 367:1519-28.
187. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P: A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-41.
188. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins, Peter DR, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis, Simon PL: Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-700.
189. Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W: A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2014, 12:1485-93.e2.
190. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W: Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012, 367:616-24.
191. Reinisch W, Villiers W de, Bene L, Simon L, Rácz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN, Hommes D, Rutgeerts P, Cortot A, Gaspari M, Cheng M, Pearce T, Sands BE: Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010, 16:233-42.
192. Sandborn WJ, Colombel J, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB: Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012, 143:62-69.e4.
193. Kaser A: Not all monoclonals are created equal - lessons from failed drug trials in Crohn 's disease. Best Pract Res Clin Gastroenterol 2014, 28:437-49.
194. Raine T, Kaser A: Seventeen in Crohn's disease: less prime than we thought? Gut 2012, 61:1653-4.
195. Mayer L, Kaser A, Blumberg RS: Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease. Gastroenterology 2012, 143:13-7.